NO20030393D0 - Effektiv ligand-mediert Ullmann-kobling av aniliner og azoler - Google Patents

Effektiv ligand-mediert Ullmann-kobling av aniliner og azoler

Info

Publication number
NO20030393D0
NO20030393D0 NO20030393A NO20030393A NO20030393D0 NO 20030393 D0 NO20030393 D0 NO 20030393D0 NO 20030393 A NO20030393 A NO 20030393A NO 20030393 A NO20030393 A NO 20030393A NO 20030393 D0 NO20030393 D0 NO 20030393D0
Authority
NO
Norway
Prior art keywords
azoles
anilines
ullmann coupling
efficient ligand
mediated ullmann
Prior art date
Application number
NO20030393A
Other languages
English (en)
Other versions
NO20030393L (no
Inventor
Jia Cheng Zhou
Pasquale N Confalone
Hui-Yin Li
Lynette M Oh
Lucius T Rossano
Charles G Clark
Christopher A Teleha
Original Assignee
Bristol Myers Squibb Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co
Publication of NO20030393D0 publication Critical patent/NO20030393D0/no
Publication of NO20030393L publication Critical patent/NO20030393L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30Oxygen or sulfur atoms
    • C07D233/32One oxygen atom
    • C07D233/38One oxygen atom with acyl radicals or hetero atoms directly attached to ring nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Executing Machine-Instructions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Peptides Or Proteins (AREA)
NO20030393A 2000-07-26 2003-01-24 Effektiv ligand-mediert Ullmann-kobling av aniliner og azoler NO20030393L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22093200P 2000-07-26 2000-07-26
PCT/US2001/023541 WO2002008199A2 (en) 2000-07-26 2001-07-26 Efficient ligand-mediated ullmann coupling of anilines and azoles

Publications (2)

Publication Number Publication Date
NO20030393D0 true NO20030393D0 (no) 2003-01-24
NO20030393L NO20030393L (no) 2003-03-24

Family

ID=22825611

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030393A NO20030393L (no) 2000-07-26 2003-01-24 Effektiv ligand-mediert Ullmann-kobling av aniliner og azoler

Country Status (22)

Country Link
US (1) US6541639B2 (no)
EP (1) EP1307431B1 (no)
JP (1) JP2004504384A (no)
KR (1) KR20030060872A (no)
CN (1) CN1444565A (no)
AT (1) ATE307804T1 (no)
AU (1) AU2001280813A1 (no)
BR (1) BR0112746A (no)
CA (1) CA2417426A1 (no)
DE (1) DE60114424T2 (no)
EC (1) ECSP034453A (no)
ES (1) ES2251501T3 (no)
HU (1) HUP0301699A3 (no)
IL (1) IL153547A0 (no)
IS (1) IS6695A (no)
MX (1) MXPA03000686A (no)
NO (1) NO20030393L (no)
NZ (1) NZ523271A (no)
PL (1) PL361233A1 (no)
RU (1) RU2003103706A (no)
WO (1) WO2002008199A2 (no)
ZA (1) ZA200300039B (no)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050026811A1 (en) * 2003-05-20 2005-02-03 Mjalli Adnan M. M. Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
DK2272813T3 (en) * 2001-04-24 2017-02-27 Massachusetts Inst Of Tech (Mit) COPPER CATALYST CREATION OF CARBON OXYGEN COMPOUNDS
EP2324830A1 (en) * 2002-03-05 2011-05-25 TransTech Pharma Inc. Process for the preparation of a monocyclic azole derivative that inhibits the interaction of ligands with rage
JP2006501159A (ja) * 2002-05-31 2006-01-12 ロデイア・シミ 炭素−炭素結合又は炭素−ヘテロ原子結合の形成方法
WO2004013094A2 (en) 2002-08-02 2004-02-12 Massachusetts Institute Of Technology Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds
AU2003270861A1 (en) * 2002-10-02 2004-04-23 Bristol-Myers Squibb Company Novel combination of a factor xa inhibitor and clopidogrel
WO2006009431A1 (en) * 2004-07-16 2006-01-26 Dsm Ip Assets B.V. Process for the preparation of an (hetero)arylamine
KR101999300B1 (ko) 2007-03-12 2019-07-12 인트라-셀룰라 써래피스, 인코퍼레이티드. 치환된 헤테로환 융합 감마-카르볼린 합성
WO2011041198A1 (en) 2009-09-30 2011-04-07 Transtech Pharma, Inc. Substituted imidazole derivatives for treatment of alzheimers disease
CA2870303A1 (en) 2012-04-14 2013-10-17 Intra-Cellular Therapies, Inc. Organic compounds
HUE053159T2 (hu) 2013-03-15 2021-06-28 Intra Cellular Therapies Inc Szerves vegyületek
IL246002B2 (en) 2013-12-03 2024-11-01 Intra Cellular Therapies Inc Converted compounds of gamma-carboline fused with heterocycles for use in the treatment of residual symptoms of psychosis and a long-acting injectable preparation containing these compounds in a matrix
JP2017509677A (ja) 2014-04-04 2017-04-06 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 有機化合物
KR20220054908A (ko) 2014-04-04 2022-05-03 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
WO2015171951A1 (en) * 2014-05-07 2015-11-12 The Regents Of The University Of Colorado, A Body Corporate 2-(4-aryl-1h-imidazol-1-yl)aniline compounds
IL318649A (en) 2016-01-26 2025-03-01 Intra Cellular Therapies Inc Organic compounds
BR112018069594B1 (pt) 2016-03-25 2023-12-05 Intra-Cellular Therapies, Inc Compostos orgânicos, composição farmacêutica compreendendo os ditos compostos e uso dos mesmos para o tratamento ou profilaxia de um distúrbio do sistema nervoso central
WO2017172795A1 (en) 2016-03-28 2017-10-05 Intra-Cellular Therapies, Inc. Novel compositions and methods
US11014925B2 (en) 2016-03-28 2021-05-25 Intra-Cellular Therapies, Inc. Co-crystals of 1-(4-fluoro-phenyl)-4-((6bR,1OaS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H- pyrido[3′,4′:4,51_pyrrolo [1,2,3-delqcuinoxalin-8-yl)-butan-1-one with nicotinamide or isonicotinamide
JP2019513143A (ja) 2016-03-28 2019-05-23 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 新規塩類および結晶
WO2018071233A1 (en) 2016-10-12 2018-04-19 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
EP3562484B1 (en) 2016-12-29 2021-08-25 Intra-Cellular Therapies, Inc. Pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline derivatives useful in the treatment of cns disorders
WO2018126140A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
IL304026B2 (en) 2017-03-24 2024-11-01 Intra Cellular Therapies Inc A pharmaceutical preparation containing 1-(4-fluoro-phenyl)-4-((Sa10,Rb6)-3-D2-2,2-methyl-2, 3, a10, 10, 9, b6- hexahydro-H7, H1- Pyrido[3',4',:4,5]pyrrolo[3,2,1-de]quioxalin-8-yl)-butan-1-one and its uses
IL272252B2 (en) 2017-07-26 2024-03-01 Intra Cellular Therapies Inc Derivatives of substituted heterocycle fused gamma-carbolines, pharmaceutical compositions comnprising them and their use in treatment
MX2020000968A (es) 2017-07-26 2020-09-28 Intra Cellular Therapies Inc Compuestos organicos.
SMT202200134T1 (it) 2018-03-08 2022-05-12 Incyte Corp Composti di amminopirazindiolo come inibitori di pi3k-y
WO2019183341A1 (en) 2018-03-23 2019-09-26 Intra-Cellular Therapies, Inc. Organic compounds
JP7476115B2 (ja) 2018-06-06 2024-04-30 イントラ-セルラー・セラピーズ・インコーポレイテッド 新規の塩および結晶
MX2020013335A (es) 2018-06-08 2021-05-27 Intra Cellular Therapies Inc Metodos novedosos.
CA3240552A1 (en) 2018-06-11 2019-12-19 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines synthesis
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
US12144808B2 (en) 2018-08-29 2024-11-19 Intra-Cellular Therapies, Inc. Compositions and methods
BR112021003838A2 (pt) 2018-08-31 2021-05-18 Intra-Cellular Therapies, Inc. métodos novos
MX2021002322A (es) 2018-08-31 2021-04-28 Intra Cellular Therapies Inc Nuevos metodos.
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
US12297200B2 (en) 2018-12-17 2025-05-13 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines synthesis
IL315005B1 (en) 2018-12-17 2025-12-01 Intra Cellular Therapies Inc Substituted heterocycle fused gamma-carbolines synthesis
MX2022000143A (es) 2019-07-07 2022-02-17 Intra Cellular Therapies Inc Metodos novedosos.
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6372658A (ja) 1986-09-17 1988-04-02 Sumitomo Chem Co Ltd ニトロジフエニルアミン類の製造方法
US5705697A (en) 1997-01-30 1998-01-06 Xerox Corporation Arylamine processes
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.

Also Published As

Publication number Publication date
ECSP034453A (es) 2003-03-31
BR0112746A (pt) 2003-09-09
DE60114424T2 (de) 2006-07-27
KR20030060872A (ko) 2003-07-16
ATE307804T1 (de) 2005-11-15
DE60114424D1 (de) 2005-12-01
HUP0301699A3 (en) 2004-03-29
US20020099225A1 (en) 2002-07-25
HUP0301699A2 (hu) 2003-12-29
WO2002008199A3 (en) 2002-06-13
IS6695A (is) 2003-01-22
NZ523271A (en) 2005-01-28
EP1307431B1 (en) 2005-10-26
JP2004504384A (ja) 2004-02-12
AU2001280813A1 (en) 2002-02-05
MXPA03000686A (es) 2003-06-06
EP1307431A2 (en) 2003-05-07
RU2003103706A (ru) 2004-08-10
CN1444565A (zh) 2003-09-24
IL153547A0 (en) 2003-07-06
CA2417426A1 (en) 2002-01-31
PL361233A1 (en) 2004-10-04
ES2251501T3 (es) 2006-05-01
ZA200300039B (en) 2004-04-02
WO2002008199A2 (en) 2002-01-31
NO20030393L (no) 2003-03-24
US6541639B2 (en) 2003-04-01

Similar Documents

Publication Publication Date Title
NO20030393D0 (no) Effektiv ligand-mediert Ullmann-kobling av aniliner og azoler
PT1131318E (pt) Processo para a producao de pirazoles 5-substituidos utilizando ditietanos
PL372799A1 (en) New compounds
EE05015B1 (et) Makseterminaliseade mgipunktiseadme hendamiseks, maksessteem ja makseprotseduuri teostamise meetod
GB0130341D0 (en) Compounds
AP1718A (en) 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors
IL139080A0 (en) Btx inhibitors and methods for their indentification and use
AU2003299585A8 (en) Water-soluble products and methods of making and using the same
MXPA03008485A (es) Derivados espirociclicos nuevos y su uso como inhibidores de fosfodiesterasa-7.
IS7258A (is) Arýloxýfenýl og arýlsúlfanýlfenýl afleiður
EA200001129A2 (ru) Способ получения 4-карбоксиамино-2-замещенного-1,2,3,4-тетрагидрохинолина
MY137541A (en) Polymerization catalyst activators, method of preparing, and their use in polymerization processes
GB0011358D0 (en) Novel use
NO20000475D0 (no) Fremgangsmåte for bruk av korrosjonsinhibitorsammensetninger og prosess for fremstilling av disse
IT1311813B1 (it) Procedimento ed apparecchiatura per la fabbricazione di lastre inmateriale lapideo.
AR022321A1 (es) Derivados de anticonvulsivo utiles para el tratamiento de la migrana transformada
BG100248A (bg) Инхибитори на скваленсинтетаза
NO20033921L (no) Inhibitor av monoaminopptak
IS2273B (is) Aðferð fyrir nýsmíðina á HIV próteasa lötum
IT1290712B1 (it) Procedimento per la produzione di lastre multistrato, relativo impianto di produzione e lastre multistrato
NO20006205L (no) Morfin-6-glukuronidsyntese
ATE312077T1 (de) Peptiddeformylase-hemmer
AU2003304490A1 (en) Peptide deformylase inhibitors
DK1387837T3 (da) Hidtil ukendte azol- eller triazolderivater, fremgangsmåden til deres fremstilling og deres anvendelse som antimykotiske lægemidler
MXPA04004526A (es) N-metil-homocisteinas, su uso y metodo para su produccion.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application